1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow L19IL2: new trials by email Literature Review of L19IL2 trials Research Report on L19IL2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors L19IL2, Ruxolitinib - Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic | Phase 1 | Not yet recruiting | Philogen S.p.A. | 96 | 2026-05-01 | 2026-05-05 |
| A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors [177Lu]Lu-OncoFAP-23, L19IL2 - FAP | Phase 1 | Recruiting | Philogen S.p.A. | 56 | 2025-10-31 | 2026-10-26 |
| A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours L19IL2 - Advanced Solid Tumours | Phase 1 / Phase 2 | Completed | Philogen S.p.A. | 33 | 2005-11-01 | 2014-02-25 |
Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1)
Philogen S.p.A. (3)
Italy (3) · Germany (1)
Filippo De Braud, Dr (1) · Manfred Johannsen, Dr (1)
2005 (1), 2023 (1), 2025 (1)